Why Glycine Was Considered for OCD Treatment
Glycine was considered for OCD treatment because it acts as an N-methyl-D-aspartate (NMDA) glutamate receptor co-agonist, targeting the glutamatergic system that has been implicated in OCD pathophysiology through genetic, neuroimaging, and cerebrospinal fluid studies showing alterations in glutamatergic metabolites and genes. 1
Neurobiological Rationale
The consideration of glycine emerged from converging evidence about glutamatergic dysfunction in OCD:
Glutamatergic neurons originating in the prefrontal cortex play a key role in cortico-striato-thalamo-cortical (CSTC) circuitry, with these neurons projecting to the striatum, and cerebrospinal fluid and magnetic resonance spectroscopy studies have indicated alterations in glutamatergic metabolites in OCD patients, though findings are not entirely consistent 1
Variants in glutamatergic genes (such as SLC1A1 and GRIN2B) are associated with OCD, and meta-analyses of genome-wide association studies have implicated several glutamatergic system genes including GRID2 and DLGAP1 1
Animal models demonstrated that mice with deletion of DLGAP3 (SAPAP3) develop defects in corticostriatal synapses and compulsive grooming behavior, providing direct mechanistic evidence linking glutamatergic dysfunction to OCD-like behaviors 1
Mechanism of Action
Glycine's therapeutic potential stems from its unique pharmacological properties:
Glycine functions as an NMDA receptor co-agonist, meaning it enhances glutamatergic neurotransmission at the NMDA receptor subtype, which is distinct from the mechanism of first-line serotonergic treatments 2, 3
By increasing synaptic glycine availability, the compound may modulate deficient signal transduction through NMDA receptors, a hypothesis supported by case reports showing robust reduction of OCD symptoms with glycine treatment 2
The glutamatergic system represents a novel therapeutic target beyond the serotonergic system, which is particularly relevant given that approximately 50% of OCD patients fail to respond adequately to first-line SSRI treatments 4, 5
Clinical Evidence Supporting Consideration
Early clinical observations provided preliminary support for glycine's potential:
A case report of treatment-refractory OCD showed robust reduction of symptoms with high-dose glycine (60g/day) over 5 years, with the patient resuming education and social life after being housebound, though symptoms partially relapsed during treatment cessation 2
A double-blind trial of adjunctive glycine in 24 adults with OCD showed those receiving glycine experienced a mean decrease of 6.04 points in Y-BOCS score compared with 1.00 point decrease for placebo, with an average 0.82 point weekly decrease that approached but did not reach statistical significance (p=0.053) 3
A systematic review found tentative evidence for glycine in OCD with an effect size of d=1.10, though this was based on methodologically weak studies with small samples 6
Important Caveats and Limitations
The clinical development of glycine faced significant practical challenges:
High dropout rates occurred in controlled trials, principally related to complaints about taste and/or nausea, with only 14 of 24 participants evaluable in one double-blind study due to regimen non-adherence 3
The required dosage of 60g/day presents substantial palatability issues, making long-term adherence difficult despite some patients continuing treatment through their regular psychiatrist for over a year 3
Evidence remains preliminary and un-replicated, precluding firm confidence in clinical effect, with the systematic review noting that while results were encouraging, more rigorous research would be needed 6
Current Treatment Context
Glycine's consideration must be understood within the broader evolution of OCD treatment:
Although no glutamatergic agent has been registered for OCD treatment yet, several have been studied in randomized controlled trials with promising results, including N-acetylcysteine (which has the strongest evidence with 3 of 5 RCTs showing positive results) and memantine (which has multiple RCTs supporting efficacy) 1, 4, 5
Sarcosine, an endogenous glycine transporter-1 antagonist that increases synaptic glycine availability, showed a 19.8% mean decrease in Y-BOCS scores in an open-label trial, with 32% of subjects achieving >35% reduction and particularly good responses in treatment-naive patients 7
The treatment algorithm for OCD positions glutamatergic agents as third-line options after optimizing SSRIs, switching medications, and considering antipsychotic augmentation, reflecting their experimental status despite mechanistic rationale 4, 5